Exelixis, Inc. EXEL was a big mover last session with its shares rising over 5% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This reverses the recent trend of the company as the stock has lost over 19% since Feb 4.
This biopharmaceutical company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate has also remained unchanged over the same period. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Exelixis currently has a Zacks Rank #3 (Hold).
Meanwhile, investors interested in the med/biomed-gene industry may consider Actelion Ltd. ALIOF, which sports a Zacks Rank #1 (Strong Buy).
Is EXEL going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment